Key facts
- This page summarizes Frank E. Thomas's Form 4 filing for Orchard Therapeutics plc.
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 03 Mar 2023, 17:00.
Frank E. Thomas - 01 Mar 2023 Form 4 Insider Report for Orchard Therapeutics plc
- Reporting relationship
- Title: President & Chief Operating Officer
- Issuer ticker
- N/A
- Reported as of
- 01 Mar 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Mar 2023, 17:00:29 UTC
- Prior SEC filing
- 13 Feb 2023
- Next SEC filing
- 14 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Frank E. Thomas
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Frank E. Thomas filed Form 4 for Orchard Therapeutics plc on 03 Mar 2023.
Change
- Previous filing in this sequence was filed on 13 Feb 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ORTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +405,600
- Change %
- Price
- $0.000000
- Shares after
- 405,600
- Date
- 01 Mar 2023
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 405,600
- Exercise price
- $0.4636
- Footnotes
- F1, F2
ORTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +179,400
- Change %
- Price
- $0.000000
- Shares after
- 179,400
- Date
- 01 Mar 2023
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 179,400
- Exercise price
- $0.5795
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments, with the first installment vesting on April 1, 2023.
Footnote F2
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
SEC remarks
Title: President & Chief Operating Officer